Mast cells are thought to contribute significantly to the pathology and mortality associated with anaphylaxis and other allergic disorders. However, studies using genetically mast cell–deficient WBB6F1-KitW/KitW-v and congenic wild-type (WBB6F1-+/+) mice indicate that mast cells can also promote health, by participating in natural immune responses to bacterial infection. We previously reported that repetitive administration of the c-kit ligand, stem cell factor (SCF), can increase mast cell numbers in normal mice in vivo. In vitro studies have indicated that SCF can also modulate mast cell effector function. We now report that treatment with SCF can significantly improve the survival of normal C57BL/6 mice in a model of acute bacterial peritonitis, cecal ligation and puncture (CLP). Experiments in mast cell–reconstituted WBB6F1-KitW/KitW-v mice indicate that this effect of SCF treatment reflects, at least in part, the actions of SCF on mast cells. Repetitive administration of SCF also can enhance survival in mice that genetically lack tumor necrosis factor (TNF)-α, demonstrating that the ability of SCF treatment to improve survival after CLP does not solely reflect effects of SCF on mast cell– dependent (or –independent) production of TNF-α. These findings identify c-kit and mast cells as potential therapeutic targets for enhancing innate immune responses.
Skip Nav Destination
Article navigation
21 December 1998
Article|
December 21 1998
The c-kit Ligand, Stem Cell Factor, Can Enhance Innate Immunity Through Effects on Mast Cells
Marcus Maurer,
Marcus Maurer
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Search for other works by this author on:
Bernd Echtenacher,
Bernd Echtenacher
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Search for other works by this author on:
Lothar Hültner,
Lothar Hültner
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Search for other works by this author on:
George Kollias,
George Kollias
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Search for other works by this author on:
Daniela N. Männel,
Daniela N. Männel
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Search for other works by this author on:
Keith E. Langley,
Keith E. Langley
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Search for other works by this author on:
Stephen J. Galli
Stephen J. Galli
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Search for other works by this author on:
Marcus Maurer
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Bernd Echtenacher
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Lothar Hültner
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
George Kollias
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Daniela N. Männel
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Keith E. Langley
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Stephen J. Galli
From the *Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; the ‡Institut für Pathologie/Tumorimmunologie, Universität Regensburg, D-93042, Regensburg, Germany; §Forschungszentrum für Umwelt und Gesundheit–Institut für Experimentelle Hämatologie, D-81337, München, Germany; the ‖Department of Molecular Genetics, Hellenic Pasteur Institute, 115 21 Athens, Greece; and ¶Amgen Inc., Thousand Oaks, California 91320
Address correspondence to Stephen J. Galli, Department of Pathology/Division of Experimental Pathology, Research North 227, Beth Israel Deaconess Medical Center-East, PO Box 15707, Boston, MA 02215. Phone: 617-667-5970; Fax: 617-667-3616; E-mail: [email protected]
B. Echtenacher and L. Hültner contributed equally to this paper.
Received:
September 09 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 188 (12): 2343–2348.
Article history
Received:
September 09 1998
Citation
Marcus Maurer, Bernd Echtenacher, Lothar Hültner, George Kollias, Daniela N. Männel, Keith E. Langley, Stephen J. Galli; The c-kit Ligand, Stem Cell Factor, Can Enhance Innate Immunity Through Effects on Mast Cells . J Exp Med 21 December 1998; 188 (12): 2343–2348. doi: https://doi.org/10.1084/jem.188.12.2343
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement